Patient-derived extracellular matrix from decellularized high-grade serous ovarian carcinoma tissues as a biocompatible support for organoid growth.

ABSTRACT: High-grade serous ovarian cancer (HGSOC) is the most common clinically diagnosed ovarian cancer, often considered a fatal disease. Although current treatments appear to provide almost complete remission, the recurrence rate is still high. Here we present an innovative tissue engineering approach applied to HGSOC by combining patient-derived decellularized extracellular matrix (dECM) and patient-derived organoids (PDO), intending to provide a three-dimensional (3D) model useful to evaluate treatment response. By histology, immunohistochemistry, immunofluorescence, and second harmonic generation microscopy, we demonstrated that dECM maintains the structural environment of native tumoral tissue. Proteomic analysis performed on isolated dECM compared to the native tumor revealed a dominant set

SUBMITTER: Sensi F 

PROVIDER: S-EPMC12496255 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature